How to Find an EGPA or Vasculitis Specialist Near You
At a Glance
To find experienced EGPA care, start with Vasculitis Foundation directories, dedicated vasculitis clinics, and academic hospitals. A rheumatologist or pulmonologist can coordinate specialists, and telehealth second opinions may help when travel is difficult.
Finding a doctor who has significant experience treating Eosinophilic Granulomatosis with Polyangiitis (EGPA) can be challenging because it is a rare disease. The most effective strategy is to use directories provided by patient advocacy groups like the Vasculitis Foundation, seek out dedicated vasculitis clinics, or look for rheumatologists and pulmonologists at academic research hospitals [1] [2].
Understanding Your Care Needs
EGPA is a complex systemic vasculitis—a condition causing inflammation of blood vessels throughout the body. It often occurs in people with asthma and eosinophilia (high levels of eosinophils, a specific type of white blood cell) and can affect multiple organs, including the lungs, sinuses, nerves, skin, kidneys, and heart [1] [2].
Because the disease can impact many body systems, specialized care is crucial. However, you do not necessarily need a doctor for every organ. Many patients benefit most from a lead clinician—usually a rheumatologist or pulmonologist experienced in systemic vasculitis—who coordinates your care and consults other experts, like cardiologists or neurologists, only when those specific organs are involved [2] [3].
Where to Look for a Specialist
When searching for a lead clinician, consider these practical starting points:
- Patient Advocacy Directories: Organizations like the Vasculitis Foundation offer specialist directories. While these listings are excellent starting points for finding doctors familiar with rare diseases, they do not universally guarantee expertise. You should still verify the doctor’s current EGPA caseload, their referral requirements, and their ability to coordinate multidisciplinary care.
- Academic Hospitals and Vasculitis Clinics: Doctors at major academic research centers are more likely to have experience with rare diseases [4]. They also stay current on modern treatments, such as targeted biotherapies (like mepolizumab), which can help maintain remission and reduce the need for oral glucocorticoids (steroids) [5] [4]. Note that while biologics are valuable tools, they are not always appropriate; life- or organ-threatening disease often requires urgent, aggressive immunosuppressants [6].
- Multisystem Care Focus: Look for clinics accustomed to screening for hidden complications. For example, cardiac involvement in EGPA can be silent but serious. An appropriate baseline cardiac evaluation—which may include an ECG, echocardiogram, blood biomarkers, or a cardiac MRI when indicated—is vital to ensure heart issues are not overlooked [7].
If You Cannot Travel
The logistical and emotional burden of finding rare-disease care is significant, and traveling to a major vasculitis center is not always possible. If you cannot travel frequently, ask your local rheumatologist or pulmonologist to request a telehealth consultation or a second-opinion review from a specialist center. The expert at the academic center can often write a comprehensive care plan and then “co-manage” (share the management of) your condition with your local medical team.
What to Do While You Wait
Do not wait for a specialist appointment if you experience emergency symptoms. Because EGPA can rapidly affect major organs, seek urgent medical evaluation if you develop new chest pain, severe breathlessness, fainting, coughing blood, sudden weakness or a “foot drop” (difficulty lifting the front part of the foot), sudden vision changes, severe abdominal pain, or markedly reduced urine [3] [2].
Additionally, never abruptly stop or change your steroid dosage or asthma medications without direct instructions from your prescribing doctor.
Preparing Your Records
Diagnosis and treatment rely on a comprehensive view of your history [8]. For example, the ANCA (antineutrophil cytoplasmic antibody) blood test is positive in only a minority of people with EGPA; a negative result does not mean you do not have the disease [1] [9].
To make the most of your consultation, gather a brief timeline of your symptoms and bring whatever records you have from the following checklist. Do not delay your appointment if you are missing some of these items—just bring what you have:
- Complete medication history (especially exact steroid doses, side effects, and any tapering history)
- Blood tests showing eosinophil counts over time and ANCA results
- Kidney function tests and urinalysis
- Chest and sinus imaging (X-rays or CT scans)
- Pulmonary function (breathing) tests
- Any previous heart evaluations (ECG, echocardiograms)
- Biopsy or pathology reports
Common questions in this guide
What kind of doctor should lead my EGPA care?
Where can I look for an EGPA specialist?
Can I get an EGPA second opinion without traveling?
How is heart involvement checked in EGPA?
What should I bring to my first EGPA specialist appointment?
Does a negative ANCA test rule out EGPA?
Which EGPA symptoms need urgent medical attention while I wait for a specialist?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.How many patients with EGPA do you currently treat, and what is your approach to co-managing care with my local doctors if I live far away?
- 2.How will you screen for silent heart involvement, and which baseline cardiac tests are appropriate for me?
- 3.Who will be my day-to-day contact for questions, and which clinician will handle my medication refills and steroid tapering?
- 4.If my disease affects multiple organ systems, how do you coordinate care with other specialists like cardiologists or neurologists?
- 5.Am I a candidate for targeted biotherapies to help reduce my steroid use, or does my current organ involvement require more aggressive immunosuppression?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
Related questions
References
References (9)
- 1
Genetic and Non-Genetic Contributions to Eosinophilic Granulomatosis with Polyangiitis: Current Knowledge and Future Perspectives.
Treccani M, Veschetti L, Patuzzo C, et al.
Current issues in molecular biology 2024; (46(7)):7516-7529 doi:10.3390/cimb46070446.
PMID: 39057087 - 2
When inflammation is not just inflammation-A review of systemic diseases of the nose and sinuses part 2: Granulomatosis with polyangiitis and eosinophilic granulomatosis with polyangiitis.
Cler SJ, Ogden MA, Farrell NF, et al.
American journal of otolaryngology 2024; (45(3)):104207 doi:10.1016/j.amjoto.2023.104207.
PMID: 38176206 - 3
Primary care physicians play a crucial role in diagnosing and managing rare eosinophilic diseases: HES and EGPA.
Shum M, Gewurz-Singer O, Silver J, Akuthota P
Frontiers in medicine 2025; (12()):1568770 doi:10.3389/fmed.2025.1568770.
PMID: 40630493 - 4
Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis.
Wechsler ME, Akuthota P, Jayne D, et al.
The New England journal of medicine 2017; (376(20)):1921-1932 doi:10.1056/NEJMoa1702079.
PMID: 28514601 - 5
Real-world safety and effectiveness of mepolizumab for patients with eosinophilic granulomatosis with polyangiitis in Japan: Long-term observation of the MARS study.
Ishii T, Kunishige H, Kobayashi T, et al.
Modern rheumatology 2025; (35(3)):505-515 doi:10.1093/mr/roae100.
PMID: 39508562 - 6
Eosinophilic Granulomatosis with Polyangiitis (Churg-Strauss).
Nguyen Y, Guillevin L
Seminars in respiratory and critical care medicine 2018; (39(4)):471-481 doi:10.1055/s-0038-1669454.
PMID: 30404114 - 7
Cardiac Involvement in Eosinophilic Granulomatosis with Polyangiitis.
Srikantharajah M, Gopalan D, Wilson-Morkeh H, et al.
Current cardiology reports 2025; (27(1)):109.
PMID: 40632386 - 8
A rare case report of polyangiitis overlap syndrome: granulomatosis with polyangiitis and eosinophilic granulomatosis with polyangiitis.
Quan MV, Frankel SK, Maleki-Fischbach M, Tan LD
BMC pulmonary medicine 2018; (18(1)):181 doi:10.1186/s12890-018-0733-2.
PMID: 30497438 - 9
Immunological Markers Associated with Skin Manifestations of EGPA.
Brunetto S, Buta F, Gangemi S, Ricciardi L
International journal of molecular sciences 2025; (26(15)) doi:10.3390/ijms26157472.
PMID: 40806600
This page is for informational purposes only and does not constitute medical advice about finding or choosing an EGPA specialist. Ask your healthcare team about urgent symptoms, medication changes, and the right care plan for your situation.
Get notified when new evidence is published on Eosinophilic granulomatosis with polyangiitis.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.